| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.29 | 4e-09 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.34 | 6e-07 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.15 | 4e-06 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.31 | 6e-06 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.13 | 8e-06 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.22 | 2e-05 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.28 | 2e-05 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.15 | 2e-05 |